FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
U2AF1 mutation	Acute Myelogenous Leukemia	U2AF1 mutation	Acute Myelogenous Leukemia	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
SF3B1 mutation	Myelodysplastic Syndrome	SF3B1 mutation	Myelodysplastic Syndrome	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
U2AF1 mutation	Myelodysplastic Syndrome	U2AF1 mutation	Myelodysplastic Syndrome	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
FLT3 mutation	Myelodysplastic Syndrome	FLT3 mutation	Myelodysplastic Syndrome	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
U2AF1 mutation	Acute Myelogenous Leukemia	U2AF1 mutation	Acute Myelogenous Leukemia	HPB-092 Sensitive: D – Preclinical HPB-092 Sensitive : D	HPB-092 Sensitive: D – Preclinical HPB-092 Sensitive : D
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	HPB-092 Sensitive: D – Preclinical HPB-092 Sensitive : D	HPB-092 Sensitive: D – Preclinical HPB-092 Sensitive : D

IRAK-4 inhibitor

IRAK-4 inhibitor

Associations(8)

Associations
(8)